A hospital in north central Arkansas has filed a complaint with the state insurance department after it said a drug manufacturer failed to follow state law regarding drug discounts outlined in the federal 340B discount program enabled by Congress.
The New York Times investigation alleges Bon Secours is failing to use the savings to help underserved populations, putting new scrutiny on the program.
Concerns about who qualifies under the 340B Program, how drugs can be dispensed to patients, and how much entities will be reimbursed may significantly impact the operation of the 340B Program as Congress intended. This evolving landscape poses challenges to all stakeholders.
On June 15, 2022, the Supreme Court issued a unanimous ruling in American Hospital Assn. v. Becerra declaring that CMS’s 2018 and 2019 reimbursement outpatient drug rate cut to 340B.